7-(Methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide compounds

By developing novel compounds that can bind to the TYK2 JH2 domain and inhibit IL-23 and IFNα signaling, the problem of insufficient effectiveness of existing treatment methods and major side effects has been solved, and effective treatment of psoriasis and other autoimmune diseases has been achieved. Reduces the risk of side effects.

CN115038705BActive Publication Date: 2024-11-08ELI LILLY & CO
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202180014348.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-02-12
Filing Date
2021-02-05
Publication Date
2024-11-08
Estimated Expiration
2041-02-05

AI Technical Summary

Technical Problem

Existing treatments for psoriasis and other autoimmune diseases such as topical and systemic therapeutic agents are not always effective and may be accompanied by various adverse side effects, especially inhibitors against TYK2 signaling have not been effective in addressing IL-23 and IFNα signaling problem.

Method used

A novel compound has been developed to treat psoriasis and other autoimmune diseases including inflammatory bowel disease, ulcerative colitis, Crohn Disease, etc. The compounds can be used in the preparation of pharmaceutical compositions and are administered orally to enhance bioavailability.

Benefits of technology

The compound is able to effectively inhibit TYK2 signaling, slow down or reverse disease progression, provides alternative treatments for psoriasis and other autoimmune diseases, reduces the risk of side effects of traditional treatments, and improves therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115038705B_ABST
    Figure CN115038705B_ABST
Patent Text Reader

Abstract

The present invention provides a compound of formula I, wherein R is (II), (III) or (IV), or a pharmaceutically acceptable salt thereof, which can be used to treat psoriasis, systemic lupus erythematosus or type 1 diabetes #imgabs0#.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to novel compounds that bind to the pseudokinase domain (JH2) of TYK2 and inhibit certain cytokine signaling, particularly IL-23 and IFNα signaling, to pharmaceutical compositions containing the compounds, to methods for using the compounds to treat certain autoimmune diseases, and to intermediates and methods that can be used to synthesize the compounds.

[0002] Psoriasis and other autoimmune diseases such as diabetes are believed to be mediated through TYK2 signaling of certain proinflammatory cytokines (see, e.g., JS Tokarski et al., J. Biol. Chem ., Vol. 290(17), pp. 11061-11074 (2015); and L. Marroqui et al., Diabetes , Vol. 64, pp. 3808-3817 (2015). Psoriasis is a chronic skin disease that is estimated to affect approximately 2% of the general population. Treatment options for psoriasis include, for example, topical treatments such as corticosteroids, phototherapy such as ultraviolet B (UVB) light, and systemic treatments such as methotrexate and apremilast. Unfortunately, such agents do not always provide effective treatment and can be associated with a variety of adverse side effects.

[0003] US 2019 / 0031664 A1 discloses certain substituted pyrazolo[1,5-a]pyrimidines that can be used to treat various inflammatory and autoimmune disorders by inhibiting TYK2. U.S. Patent No. 7,557,110 discloses certain pyrazolo[1,5-a]pyrimidine derivatives as kinase inhibitors that can be used to treat kinase-mediated disorders such as inflammatory diseases and autoimmune diseases.

[0004] There is a need for alternative treatments for autoimmune diseases, such as psoriasis, systemic lupus erythematosus (SLE), and diabetes. In particular, there is a need for compounds that bind to the TYK2 JH2 domain. Furthermore, there is a need for compounds that bind to the TYK2 JH2 domain and inhibit IL-23 and IFNα signaling.

[0005] Therefore, in one embodiment, the present invention provides a compound of formula I:

[0006]

[0007] Where R is:

[0008]

[0009] or a pharmaceutically acceptable salt thereof.

[0010] In a specific embodiment, the compound has Formula Ia:

[0011]

[0012] or a pharmaceutically acceptable salt thereof.

[0013] In a particular embodiment, the compound has Formula Ib:

[0014]

[0015] or a pharmaceutically acceptable salt thereof.

[0016] In one embodiment, R is:

[0017]

[0018] or a pharmaceutically acceptable salt thereof.

[0019] In one embodiment, R is:

[0020]

[0021] or a pharmaceutically acceptable salt thereof.

[0022] In one embodiment, R is:

[0023]

[0024] or a pharmaceutically acceptable salt thereof.

[0025] In one embodiment, the compound is:

[0026]

[0027] or a pharmaceutically acceptable salt thereof.

[0028] In one embodiment, the compound is:

[0029]

[0030] or a pharmaceutically acceptable salt thereof.

[0031] In one embodiment, the compound is:

[0032]

[0033] or a pharmaceutically acceptable salt thereof.

[0034] In one embodiment, the present invention also provides a method for treating psoriasis in a patient in need of such treatment, comprising administering to the patient an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In one embodiment, the present invention further provides a method for treating SLE in a patient in need of such treatment, comprising administering to the patient an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof. In one embodiment, the present invention further provides a method for treating a disease selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriatic arthritis, rheumatoid arthritis (RA), alopecia areata, atopic dermatitis, axial spondyloarthritis, multiple sclerosis (MS), type 1 diabetes, type 2 diabetes, and latent autoimmune diabetes in adults (LADA) in a patient in need of such treatment, comprising administering to the patient an effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.

[0035] In one embodiment, the present invention further provides a compound of formula I for treatment or a pharmaceutically acceptable salt thereof. In one embodiment, the present invention provides a compound of formula I for treatment of psoriasis or a pharmaceutically acceptable salt thereof. In one embodiment, the present invention provides a compound of formula I for treatment of SLE or a pharmaceutically acceptable salt thereof. In one embodiment, the present invention also provides a compound of formula I for treatment of a disease selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriatic arthritis, RA, alopecia areata, atopic dermatitis, axial spondyloarthritis, MS, type 1 diabetes, type 2 diabetes and LADA or a pharmaceutically acceptable salt thereof.

[0036] In one embodiment, the present invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for treating psoriasis. In one embodiment, the present invention provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for treating SLE. In one embodiment, the present invention also provides the use of a compound of formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for treating a disease selected from inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriatic arthritis, RA, alopecia areata, atopic dermatitis, axial spondyloarthritis, MS, type 1 diabetes, type 2 diabetes and LADA.

[0037] In one embodiment, the present invention further provides a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers, diluents or excipients. In one embodiment, the present invention further provides a method for preparing a pharmaceutical composition comprising mixing a compound of formula I or a pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carriers, diluents or excipients. In one embodiment, the present invention also encompasses novel intermediates and methods for synthesizing compounds of formula I.

[0038] As used herein, the term "treating" includes limiting, slowing, stopping or reversing the progression or severity of existing symptoms or conditions.

[0039] The term "patient" as used herein refers to a mammal, particularly a human.

[0040] The term "effective amount" as used herein refers to the amount or dosage of a compound of the present invention or a pharmaceutically acceptable salt thereof, which provides the desired effect in a patient being diagnosed or treated when administered to the patient in single or multiple doses.

[0041] The effective amount can be determined by one skilled in the art by using known techniques and by observing the results obtained under similar circumstances. In determining the effective amount for a patient, the attending diagnostician will consider many factors, including, but not limited to: the species of the patient; its size, age, and general health; the specific disease or condition involved; the extent or severity of the disease or condition involved; the response of the individual patient; the specific compound being administered; the mode of administration; the bioavailability characteristics of the administered formulation; the dosage regimen selected; concurrent medications; and other relevant circumstances.

[0042] The compounds of the present invention are configured as pharmaceutical compositions, which are administered by any route that makes the compound bioavailable. Most preferably, such compositions are used for oral administration. Such pharmaceutical compositions and methods for their preparation are well known in the art (see, for example, Remington: The Science and Practice of Pharmacy, LV Allen, author, 22nd edition, Pharmaceutical Press, 2012).

[0043] The compounds of formula I or their pharmaceutically acceptable salts are particularly useful in the therapeutic methods of the present invention, and all configurations thereof (including enantiomers) and mixtures thereof (including racemates) are contemplated within the scope of the present invention. It is to be understood that these configurations are applicable to the therapeutic methods and compounds of the present invention.

[0044] Certain intermediates described in the preparations below may contain one or more nitrogen protecting groups. It is to be understood that the protecting groups may vary depending on the specific reaction conditions and the specific transformation to be performed as will be appreciated by those skilled in the art. Protection and deprotection conditions are well known to those skilled in the art and are described in the literature (see, e.g., " Greene's Protective Groups in Organic Synthesis ”, 4th ed., Peter GM Wuts and Theodora W. Greene, John Wiley and Sons, Inc. 2007).

[0045] Individual isomers (including enantiomers) may be separated or resolved by one of ordinary skill in the art at any convenient point in the synthesis of the compounds of the invention by methods such as selective crystallization techniques or chiral chromatography (see, e.g., J. Jacques et al., “ Enantiomers, Racemates, and Resolutions ”, John Wiley and Sons, Inc., 1981 and EL Eliel and SH Wilen, “ Stereochemistry of Organic Compounds ”, Wiley-Interscience, 1994).

[0046] Pharmaceutically acceptable salts of the compounds of the invention can be formed, for example, by reacting an appropriate free base of the compounds of the invention, an appropriate pharmaceutically acceptable acid in a suitable solvent (e.g., diethyl ether) under standard conditions well known in the art. In addition, the formation of such pharmaceutically acceptable salts can occur simultaneously with the deprotection of the nitrogen protecting group. See, for example, Gould, PL, "Salt selection for basic drugs," International Journal of Pharmaceutics , 33:201-217 (1986); Bastin, RJ et al., “Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities,” Organic Process Research and Development , 4: 427-435 (2000); and Berge, SM et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Sciences , 66: 1-19, (1977).

[0047] Certain abbreviations are defined as follows: “BINAP” means (±)-2,2′-bis(diphenylphosphino)-1,1′-binaphthyl; “BOP” means (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate; “BrettPhos” means dicyclohexyl[3,6-dimethoxy-2′,4′,6′-tri(1-methylethyl)[1,1′-biphenyl]-2-yl]phosphine; “DCM” means dichloromethane; “DEM” means diethyl malonate; “DIEA” means N,N-diisopropylethylamine; “DMEM” means Dupic's modified Egger's medium; “DMF” means N,N-dimethylformamide; “DMSO” means dimethyl sulfoxide; “EtOAc” means ethyl acetate; “EtOH” means ethanol and ethyl acetate. "FBS" refers to fetal bovine serum; "HATU" refers to 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate; "HEPES" refers to 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; "HPLC" refers to high performance liquid chromatography; "IFNα" refers to interferon α; "IL-2" refers to interleukin 2; "IL-23" refers to interleukin 23; "JAK" refers to Janus kinase; "LiHMDS" refers to lithium hexamethyldisilazide; "MeI" refers to methyl iodide; "MeNH2" refers to methylamine; "MeOH" refers to methanol and methyl alcohol; "MTBE" refers to methyl tert-butyl ether; "NaOEt" refers to sodium ethoxide; "Pd-175 "[tBuBrettPhos Pd(allyl)]OTf" refers to allyl(2-di-tert-butylphosphino-3,6-dimethoxy-2',4',6'-triisopropyl-1,1'-biphenyl)palladium(II) trifluoromethanesulfonate; "RPM" refers to revolutions per minute; "RPMI" refers to Roswell Park Memorial Institute; "TEA" refers to triethylamine; "THF" refers to tetrahydrofuran; "TYK2" refers to tyrosine kinase 2; "UVB" refers to ultraviolet B; and "STAT" refers to signal transducer and activator of transcription.

[0048] The compounds of the present invention or their pharmaceutically acceptable salts can be prepared by a variety of procedures known to those of ordinary skill in the art, some of which are described in the following schemes, preparation examples and examples. The product of each step in the following scheme can be recovered by conventional methods known in the art, including extraction, evaporation, precipitation, chromatography, filtration, grinding and crystallization. In the following scheme, unless otherwise stated, all substituents are as defined above. Reagents and raw materials are easily available to those of ordinary skill in the art. Without limiting the scope of the invention, the following schemes, preparation examples and examples are provided to further illustrate the present invention.

[0049] Solution 1

[0050]

[0051] In Scheme 1, step A, the formation of compound (2) is shown as an amide coupling between compound (1) and MeNH2 using a suitable organic base such as DIEA and a suitable coupling agent such as HATU in a solvent such as DMF at 0-22°C under conditions well known in the art.

[0052] In step B, MeI is added to compound (2) to form dimethylsulfonium iodide salt, followed by treatment with a suitable base such as LiHMDS in a suitable solvent such as THF at 0-22°C to obtain the cyclized compound (3).

[0053] In step C, compound (3) is deprotected under standard conditions using a suitable acid such as 4-methylbenzenesulfonic acid in a suitable solvent such as acetonitrile at about 55°C, followed by the addition of a solvent such as MTBE to precipitate compound (4).

[0054] Solution 2

[0055]

[0056] In Scheme 2, step A, Buchwald coupling is carried out between compound (5) and substituted bromopyridine using CuI and a suitable base such as potassium carbonate in a suitable solvent such as DMF and 1,4-dioxane to obtain compound (6). In some cases, N',N'-dimethylethane-1,2-diamine may also be added to the reaction mixture.

[0057] Step B depicts the deprotection of compound (6) by hydrogenation using a suitable catalyst such as 10% Pd / C or 20% Pd(OH)2 / C in a solvent such as EtOH or MeOH under a pressurized hydrogen atmosphere to obtain compound (7).

[0058] Solution 3

[0059]

[0060] Scheme 3, step A depicts the addition of DEM to compound (8) and subsequent cyclization to compound (9) using a suitable base such as NaOEt or potassium tert-butoxide at about 80°C in a solvent such as EtOH.

[0061] In step B, the 7-hydroxy and 5-oxo groups of compound (9) can be chlorinated using a suitable chlorine source such as POCl3 and a suitable organic base such as pyridine at about 50-100°C in a suitable solvent such as acetonitrile to obtain compound (10).

[0062] In step C, selective nucleophilic aromatic substitution on the 7-chloro group of compound (10) can be carried out under conditions well known in the art using an appropriate nucleophile such as MeNH2 in a suitable solvent such as THF at ambient temperature to afford compound (11).

[0063] In step D, compound (11) can be subjected to Buchwald coupling with compound (7) using a suitable catalyst and ligand system such as Pd-175 [tBuBrettPhos Pd(allyl)]OTf and a suitable base such as potassium acetate in a suitable solvent such as 2-methyl-2-butanol under heating at 100°C to form compound (12).

[0064] Compound (12) can be treated with a suitable base such as aqueous LiOH in a suitable solvent system such as EtOH and THF at reflux to obtain compound (13) via basic hydrolysis of the ester as shown in step E.

[0065] Step F depicts an amide coupling between compound (13) and compound (4) to form a compound of Formula Ia using a suitable organic base such as DIEA and a suitable coupling agent such as BOP in a solvent such as DMF under conditions well known in the art.

[0066] Solution 4

[0067]

[0068] Scheme 4, step A depicts the basic hydrolysis of compound (11) with a suitable base such as aqueous NaOH in a solvent such as 1,4-dioxane at 50°C to afford compound (14).

[0069] Step B shows an amide coupling between compounds (14) and (15) using the conditions generally described in Scheme 3, Step F to afford compound (16).

[0070] In step C, Buchwald coupling between compound (16) and (7) can be carried out using a suitable catalyst and ligand system such as Pd-175 [tBuBrettPhos Pd(allyl)]Otf or allylpalladium(II) chloride dimer and BINAP with a suitable base such as potassium acetate in an appropriate solvent volume such as 1,4-dioxane and 2-methyl-2-butanol with heating at 120-140°C to obtain the compound of formula Ia.

[0071] Preparation Example 1

[0072] tert-Butyl N-[(1R)-1-(Methylcarbamoyl)-3-methylsulfanyl-propyl]carbamate

[0073]

[0074] Scheme 1 Step A: A solution of (tert-butoxycarbonyl)-D-methionine (400 g, 1.6 mol), methylamine hydrochloride (162.47 g, 2.4 mol) and DIEA (700 ml, 4.01 mol) in DMF (4 L) was cooled to 0 °C and HATU (732.1 g, 1.92 mol) was added. The reaction was warmed to ambient temperature. After stirring for 2 hours, the solvent was evaporated. Water (10 L) was then added and the aqueous solution was extracted with DCM (2 x 3 L). The organic layers were combined, washed with saturated aqueous sodium bicarbonate solution (3 L), dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with EtOAc in hexanes to obtain the title compound (368 g, 87%) as a white solid. ES / MS m / z 263 (M+H).

[0075] Preparation Example 2

[0076] N-[(3R)-1-Methyl-2-oxo-pyrrolidin-3-yl]carbamic acid tert-butyl ester

[0077]

[0078] Scheme 1, Step B: A mixture of tert-butyl N-[(1R)-1-(methylcarbamoyl)-3-methylsulfanyl-propyl]carbamate (368 g, 1.40 mol) and MeI (3.68 L, 59.11 mol) was stirred at ambient temperature for 18 hours. The mixture was then concentrated in vacuo. A portion of the resulting crude dimethylsulfonium iodide salt (210 g, 0.52 mol) was dissolved in THF (4.7 L), cooled to 0 °C under nitrogen, and LiHMDS (1.00 M solution in THF, 1.16 L, 1.16 mol) was added dropwise. The reaction mixture was then warmed to ambient temperature. After 4 hours, water (2.4 L) was added and the solvent was concentrated to half volume. The mixture was extracted with DCM (2 x 3 L). The organics were combined and concentrated in vacuo. The residue was purified by silica gel chromatography eluting with MeOH in DCM to afford the title compound as a white solid (50 g). ES / MS m / z 215 (M+H). Chiral HPLC: R t(retention time) = 9.13 min; LC column: ChiralPAc IA OD 4.6×250 mm 5 µm; Isocratic: 0.1% diethylamine / hexane / ethanol (85 / 15); Column temperature: 25°C; Flow rate: 1.0 mL / min.

[0079] Optical rotation: [α] D 20 = +53 ° (C=0.5, MeOH).

[0080] Preparation Example 3

[0081] (3R)-3-Amino-1-methyl-pyrrolidin-2-one; 4-methylbenzenesulfonic acid

[0082]

[0083] Scheme 1, Step C: A mixture of tert-butyl N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]carbamate (46 g, 214.69 mmol) and 4-methylbenzenesulfonic acid (74.5 g, 433 mmol) in acetonitrile (500 mL) was heated and stirred at 55°C for 4 hours. MTBE (1 L) was then added and the mixture was cooled to 22°C. The resulting solid was collected by filtration, washed with additional MTBE, and dried in vacuo to constant weight to afford the title compound as a white solid (60 g, 95%). ES / MS m / z 115 (M+H).

[0084] Optical rotation: [α] D 20 = +31.3 ° (C=0.5, MeOH).

[0085] Preparation Example 4

[0086] Benzyl N-[1-(5-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]carbamate

[0087]

[0088] Scheme 2 Step A: A high pressure vessel was charged with benzyl N-(2-oxo-1H-pyridin-3-yl)carbamate (6 g, 24 mmol), cuprous iodide (0.9 g, 5 mmol), 2-bromo-5-methylpyridine (3.75 g, 21.4 mmol), potassium carbonate (7 g, 51 mmol), 1,4-dioxane (130 ml) and DMF (0.5 ml). The reaction was heated at 110 °C for 4 hours. The mixture was cooled to ambient temperature, filtered through celite, and washed with 1,4-dioxane. The filtrate was concentrated in vacuo to obtain a dark brown oil. The resulting residue was purified by flash chromatography on silica gel eluting with 0-60% EtOAc / hexanes over 25 minutes to obtain the title compound (5 g, 62%) as a pale white solid. ES / MS m / z 336 (M+H).

[0089] Preparation Example 5

[0090] Benzyl N-[2-oxo-1-(2-pyridinyl)-3-pyridinyl]carbamate

[0091]

[0092] Scheme 2 Step A: A high pressure vessel was charged with benzyl N-(2-oxo-1H-pyridin-3-yl)carbamate (10.10 g, 41.36 mmol), cuprous iodide (1.6 g, 8.6 mmol), 2-bromopyridine (5.2 ml, 54 mmol), potassium carbonate (11.8 g, 86 mmol), 1,4-dioxane (200 ml), and N',N'-dimethylethane-1,2-diamine (2 ml, 17.4 mmol). The reaction was heated at 115°C for 18 hours. The mixture was cooled to ambient temperature and filtered through celite. The filtrate was concentrated in vacuo to obtain a brown oil. The resulting residue was purified by flash chromatography on silica gel eluting with 0-60% EtOAc / hexanes over 30 minutes to obtain the title compound (10.14 g, 76%) as a white solid. ES / MS m / z 322.0 (M+H).

[0093] Preparation Example 6

[0094] Benzyl N-[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]carbamate

[0095]

[0096] Scheme 2 Step A: A high pressure vessel was charged with benzyl N-(2-oxo-1H-pyridin-3-yl)carbamate (9.8 g, 40 mmol), cuprous iodide (1.9 g, 10 mmol), 2-bromo-6-methylpyridine (5.9 ml, 51 mmol), potassium carbonate (11 g, 80 mmol), N',N'-dimethylethane-1,2-diamine (2 ml) and 1,4-dioxane (190 ml). The reaction was heated at 115°C for 5 hours. The mixture was cooled to ambient temperature and filtered through celite. The filtrate was concentrated in vacuo to obtain a brown oil. The resulting residue was purified by flash chromatography on silica gel eluting with 0-50% EtOAc / hexanes over 30 minutes to obtain the title compound (7.77 g, 58%) as a white solid. ES / MS m / z 336.0 (M+H).

[0097] Preparation Example 7

[0098] 3-Amino-1-(5-methyl-2-pyridyl)pyridin-2-one

[0099]

[0100] Scheme 2, Step B: A Parr shaker was purged with nitrogen and charged with 10% Pd / C (1.27 g, 1.19 mmol). The Parr shaker was purged with nitrogen and then charged with MeOH (25 mL) and benzyl N-[1-(5-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]carbamate (5.0 g, 15 mmol) dissolved in MeOH (25 mL) and EtOAc (10 mL). The Parr shaker was sealed, purged with nitrogen, then hydrogen, and pressurized to 138 kPa. The mixture was stirred at 30 °C for 20 minutes. The reaction mixture was filtered and the solvent was concentrated in vacuo to obtain the title compound (2.7 g, 90%) as a yellow solid. ES / MS m / z 202 (M+H).

[0101] Preparation Example 8

[0102] 3-Amino-1-(2-pyridyl)piperidin-2-one

[0103]

[0104] Scheme 2, Step B: A Parr shaker was purged with nitrogen and charged with 20% Pd(OH)2 / C (5.7 g, 41 mmol). The Parr shaker was purged with nitrogen and then charged with EtOH (200 mL) and N-[2-oxo-1-(2-pyridinyl)-3-pyridinyl]carbamic acid benzyl ester (9.2 g, 29 mmol) dissolved in EtOH (200 mL). The Parr shaker was sealed, purged with nitrogen, then hydrogen, and pressurized to 48 kPa. The mixture was stirred at ambient temperature for 50 minutes. The reaction mixture was filtered and the solvent was concentrated in vacuo to obtain the title compound (5.3 g, 99%) as a yellow solid. ES / MS m / z 188.0 (M+H).

[0105] Preparation Example 9

[0106] 3-Amino-1-(6-methyl-2-pyridyl)pyridin-2-one

[0107]

[0108] Scheme 2 Step B: 20% Pd(OH)2 / C (7.7 g, 55 mmol) was loaded into a Parr shaker purged with nitrogen. The Parr shaker was purged with nitrogen and then EtOH (200 ml) and N-[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]benzyl carbamate (7.77 g, 23 mmol) dissolved in EtOH (200 ml) were loaded. The Parr shaker was sealed, purged with nitrogen, then purged with hydrogen, and pressurized to 62 kPa. The mixture was stirred at ambient temperature for 55 minutes. The reaction mixture was filtered and the solvent was concentrated in vacuo to a viscous oil. The crude material was suspended in DCM (40 ml) and hexane was added with stirring until a precipitate was formed. The mixture was filtered and air dried to obtain the title compound (3.0 g, 51%) as a tan solid. ES / MS m / z 202.0 (M+H).

[0109] Preparation Example 10

[0110] 7-Hydroxy-5-oxo-4H-pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0111]

[0112] Scheme 3 Step A: Ethyl 5-amino-1H-pyrazole-4-carboxylate (12.5 g, 80.6 mmol) and DEM (18.5 mL, 121 mmol) were dissolved in EtOH (90 mL). To the mixture was added NaOEt (21 mass % in EtOH, 45.1 mL, 121 mmol) and the reaction was stirred at 90 °C for 24 hours. Thereafter, the reaction was cooled to ambient temperature. The mixture was then made acidic with 5N aqueous HCl and the resulting precipitate was filtered to obtain the title compound (11.7 g, 65.1%) as a white solid. ES / MS m / z 224 (M+H).

[0113] Alternative Preparation Example 10

[0114] Scheme 3 Step A: To a solution of ethyl 5-amino-1H-pyrazole-4-carboxylate (400 g, 2.58 mol) and DEM (584 ml, 3.87 mol) in EtOH (6.00 L) at 25°C under nitrogen was added potassium tert-butoxide (578 g, 5.16 mol). The solution was stirred at 80°C for 12 hours and then the reaction was cooled to 22°C. The reaction mixture was diluted with 0.1N HCl (2 L) and the pH was adjusted to 3 with 5N HCl. The mixture was filtered and the filter cake was washed with water (800 ml). The solid was dried in vacuo to constant weight to afford the title compound (460 g, 81%) as an off-white solid. ES / MS m / z 224 (M+H).

[0115] Preparation Example 11

[0116] Ethyl 5,7-dichloropyrazolo[1,5-a]pyrimidine-3-carboxylate

[0117]

[0118] Scheme 3, Step B: Ethyl 7-hydroxy-5-oxo-4H-pyrazolo[1,5-a]pyrimidine-3-carboxylate (11.7 g, 52.4 mmol) was suspended in acetonitrile (50 ml) and purged with nitrogen for 5 minutes. To the mixture was added POCl3 (14.8 ml, 157 mmol) at 50°C followed by pyridine (4.28 ml, 52.4 mmol) and the reaction was then stirred at 100°C for 5 hours. Thereafter, the reaction was cooled to ambient temperature and poured into an ice / water mixture. The mixture was neutralized with saturated aqueous sodium bicarbonate solution and the resulting precipitate was filtered to obtain the title compound (13 g, 95.3%) as a white solid. ES / MS m / z ( 35 Cl / 37 Cl) 260 / 262 [M+H]+ .

[0119] Alternative Preparation Example 11

[0120] Scheme 3, Step B: To a suspension of ethyl 7-hydroxy-5-oxo-4H-pyrazolo[1,5-a]pyrimidine-3-carboxylate (400 g, 1.79 mol) in acetonitrile (2 L) at 50 °C under nitrogen was added POCl3 (416 mL, 4.48 mol) and pyridine (217 mL, 2.69 mol) dropwise. The reaction was stirred at 80 °C for 12 hours. The reaction mixture was concentrated in vacuo and the residue was poured into water (2 L). The reaction mixture was filtered and the solid was washed with water (800 mL). The solid was dried in vacuo to constant weight to obtain the title compound (360 g, 66%) as an orange solid. ES / MS m / z ( 35 Cl / 37 Cl) 260 / 262 [M+H] + .

[0121] Preparation Example 12

[0122] Ethyl 5-chloro-7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylate

[0123]

[0124] Scheme 3, Step C: Ethyl 5,7-dichloropyrazolo[1,5-a]pyrimidine-3-carboxylate (50.0 g, 192 mmol) was added to THF (250 mL) and the solution was cooled to 10°C. A solution of MeNH2 (33% w / w in EtOH) (79 mL, 634 mmol) was then added, keeping the temperature below 20°C. The reaction mixture was stirred and warmed to 22°C and stirred for 4 hours. Water (300 mL) was then added and the mixture was stirred for an additional 1 hour.

[0125] The resulting solid was collected by filtration and washed with a THF / water mixture (2:3) (100 mL) and water (400 mL). The solid was then dried under vacuum (10 mbar / 50° C.) to constant weight to afford the title compound (49.5 g, 90%) as a light brown solid. ES / MS m / z ( 35 Cl / 37 Cl) 255 / 257 [M+H] + .

[0126] Preparation Example 13

[0127] 5-Chloro-7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0128]

[0129] Scheme 4 Step A: 1N NaOH (50 mL, 50 mmol) was added to ethyl 5-chloro-7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylate (9.05 g, 35.5 mmol) in 1,4-dioxane (50 mL) and the mixture was warmed to 50°C. After 16 hours, the mixture was cooled to ambient temperature and the pH was adjusted to ~3 by adding 1N HCl. The resulting solid was collected and dried in vacuo to afford the title compound as a light tan solid (8.0 g, >99%). ES / MS m / z ( 35 Cl / 37 Cl) 227 / 229 [M+H] + .

[0130] Preparation Example 14

[0131] 5-Chloro-7-(methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0132]

[0133] Scheme 4, step B: To a mixture of 5-chloro-7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (4.3 g, 19 mmol) and (R)-3-amino-1-methyl-pyrrolidin-2-one (2.4 g, 21 mmol) in DMF (95 ml) was added DIEA (14 ml, 80 mmol) and BOP (11 g, 24 mmol). The mixture was stirred at ambient temperature for 2 hours and then quenched with water to form an off-white solid. The resulting solid was filtered and dried under vacuum at ambient temperature to afford the title compound (5 g, 82%) as an off-white solid. ES / MS m / z 323 (M+H).

[0134] Preparation Example 15

[0135] 7-(Methylamino)-5-[[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid ethyl ester

[0136]

[0137] Scheme 3, Step D: A round bottom flask was charged with ethyl 5-chloro-7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxylate (2 g, 7.8 mmol), potassium acetate (2.2 g, 15.7 mmol) and 2-methylbutan-2-ol (25 ml). The flask was flushed with nitrogen for 5 minutes. Pd-175 [tBuBrettPhos Pd(allyl)]Otf (184 mg, 0.24 mmol) and acetic acid (0.045 ml, 0.79 mmol) were added. The mixture was heated at 100°C for 18 hours. The mixture was then cooled to ambient temperature and diluted with DCM / water (30 ml). The mixture was filtered and dried under vacuum at ambient temperature to obtain the title compound (2.4 g, 73%). ES / MS m / z 420.0 (M+H).

[0138] Preparation Example 16

[0139] 7-(Methylamino)-5-[[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid

[0140]

[0141] Scheme 3, Step E: A round bottom flask was charged with ethyl 7-(methylamino)-5-[[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxylate (2.4 g, 5.7 mmol), EtOH (20 mL) and lithium hydroxide (0.34 g, 4.1 mmol) dissolved in water (12 mL). The mixture was heated to reflux under nitrogen for 18 h and then cooled to ambient temperature. The pH was adjusted to ~2 by adding 1N HCl. After stirring for 30 min, the resulting solid was filtered, washed with ice-cold water (20 mL) and dried under vacuum at ambient temperature to afford the title compound (1.6 g, 71%). ES / MS m / z 392.0 (M+H).

[0142] Preparation Example 17

[0143] Preparation of tracer for TYK2-JH2 tracer binding assay

[0144] (2E)-2-[(2E,4E)-5-[3-[6-[4-[4-[[5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-6-(methylcarbamoyl)-1,2,4-triazin-3-yl]amino]pyrazol-1-yl]-1-piperidinyl]-6-oxo-hexyl]-3-methyl-5-sulfonato-1-(3-sulfonatopropyl)indol-1-ium-2-yl]penta-2,4-dienylidene]-3,3-dimethyl-1-(3-sulfonatopropyl)indoline-5-sulfonate; triethylammonium

[0145] 2-Methoxy-3-(1-methyl-1,2,4-triazol-3-yl)aniline (5.95 g, 29.1 mmol) was added to 5-chloro-3-methylsulfanyl-1,2,4-triazine-6-carboxylic acid ethyl ester (6.8 g, 29.0 mmol) in NMP (20 ml) and stirred at ambient temperature. After 90 minutes, diethyl ether (100 ml) was added and the mixture was stirred for 15 minutes. The resulting solid was filtered and washed with diethyl ether. The solid was partitioned between DCM and saturated aqueous sodium bicarbonate solution. The organic layer was further washed with saturated aqueous sodium chloride solution, dried over sodium sulfate, filtered and evaporated to obtain 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-3-methylsulfanyl-1,2,4-triazine-6-carboxylic acid ethyl ester (10.12 g, 82%) as a light yellow solid. ES / MS m / z 402.2 (M+H).

[0146] 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-3-methylsulfanyl-1,2,4-triazine-6-carboxylic acid ethyl ester (10.12 g, 23.7 mmol) was stirred in 2M MeNH2 in THF (75 mL, 150 mmol) at ambient temperature for 4 h. Diethyl ether (100 mL) was added and the mixture was stirred for 15 min. The resulting solid was collected, washed with diethyl ether (50 mL) and dried in vacuo to afford 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-methyl-3-methylsulfanyl-1,2,4-triazine-6-carboxamide (8.03 g, 78%) as a light yellow solid. ES / MS m / z 387.0 (M+H).

[0147] Meta-chloroperbenzoic acid (703 mg, 3.14 mmol) was added to a suspension of 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-methyl-3-methylsulfanyl-1,2,4-triazine-6-carboxamide (500 mg, 1.26 mmol) in DMF (12.5 ml) at 0°C and allowed to warm to ambient temperature. After 30 minutes, tert-butyl 4-(4-aminopyrazol-1-yl)piperidine-1-carboxylate (520 mg, 1.89 mmol) was added and the mixture was stirred at ambient temperature. After 24 hours, the mixture was partitioned between DCM and saturated aqueous sodium bicarbonate solution. The organic layer was dried over magnesium sulfate, filtered and evaporated. The resulting solid was triturated several times with diethyl ether and dried in vacuo to afford tert-butyl 4-[4-[[5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-6-(methylcarbamoyl)-1,2,4-triazin-3-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate (720 mg, 81%) as a 86% pure yellow solid. ES / MS m / z 605.2 (M+H).

[0148] To a suspension of tert-butyl 4-[4-[[5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-6-(methylcarbamoyl)-1,2,4-triazin-3-yl]amino]pyrazol-1-yl]piperidine-1-carboxylate (720 mg, 1.0 mmol) in MeOH (5 mL) was added 4N HCl in dioxane (2.5 mL, 10 mmol) and stirred at ambient temperature. After 72 h, the mixture was evaporated. The resulting material was partitioned between DCM (100 mL) and water (20 mL). The pH of the aqueous layer was adjusted to >8 by adding 1N NaOH and extracted with 3:1 chloroform / isopropanol. The organic layers were combined, dried over magnesium sulfate, filtered and evaporated. The resulting solid was triturated with diethyl ether and then dried in vacuo to afford 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-methyl-3-[[1-(4-piperidinyl)pyrazol-4-yl]amino]-1,2,4-triazine-6-carboxamide (585 mg, 97%) as a 86% pure yellow solid. ES / MS m / z 505.0 (M+H).

[0149] (2E)-2-[(2E,4E)-5-[3-[6-(2,5-dioxopyrrolidin-1-yl)oxy-6-oxo-hexyl]-3-methyl-5-sulfonato-1-(3-sulfonatopropyl)indol-1-ium-2-yl]penta-2,4-dienylidene]-3,3-dimethyl-1-(3-sulfonatopropyl)indoline-5-sulfonic acid triethylammonium (10 mg, 0.008 mmol) The solution in DMSO (1 mL) was added to a solution of 5-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-methyl-3-[[1-(4-piperidinyl)pyrazol-4-yl]amino]-1,2,4-triazine-6-carboxamide (4.5 mg, 0.008 mmol) and TEA (0.002 mL, 0.014 mmol) in DMSO (1 mL). The reaction vial was wrapped in aluminum foil to protect from light and stirred at ambient temperature overnight. The resulting residue was purified by preparative HPLC (Kinetix EVO C18 30 mm×100 mm, 5 μm) eluting with 0 to 20% acetonitrile in water to afford the title compound (8.5 mg, 65%) as a bright blue solid. ES / MS m / z 673.4 (M+H).

[0150] Example 1

[0151] 7-(Methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]-5-[[1-(5-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0152]

[0153] Scheme 4, Step C: A microwave vessel was charged with 5-chloro-7-(methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (76 mg, 0.23 mmol), 3-amino-1-(5-methyl-2-pyridinyl)pyridin-2-one (72 mg, 0.359 mmol), potassium acetate (48 mg, 0.47 mmol), 2-methylbutan-2-ol (0.8 ml) and 1,4-dioxane (0.8 ml). The flask was flushed with nitrogen for 5 minutes. BINAP (59 mg, 0.093 mmol) and allylpalladium(II) chloride dimer (16.7 mg, 0.0447 mmol) were added. The vessel was heated in a microwave at 120°C. After 20 minutes, the mixture was cooled to ambient temperature and filtered through celite. The resulting residue was purified by reverse phase chromatography to afford the title compound (87 mg, 75%). ES / MS m / z488.2 (M+H).

[0154] Example 2

[0155] 7-(Methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]-5-[[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0156]

[0157] Scheme 3, Step F: To a mixture of 7-(methylamino)-5-[[1-(6-methyl-2-pyridinyl)-2-oxo-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxylic acid (1.2 g, 3.1 mmol) and (3R)-3-amino-1-methyl-pyrrolidin-2-one; 4-methylbenzenesulfonic acid (0.9 g, 3 mmol) in DMF (15 ml) was added DIEA (2.1 ml, 12 mmol) and BOP (1.8 g, 3.9 mmol). After stirring at ambient temperature for 1 hour, the reaction mixture was added to water (240 ml) and the pH was adjusted to ~6-7. After stirring for 30 minutes, the solid was filtered, washed with ice-cold water (20 ml) and dried under vacuum at ambient temperature. The residue was purified via reverse phase chromatography and recrystallized from MeOH to obtain the title compound (446 mg, 30%). ES / MS m / z 488.2 (M+H).

[0158] Example 3

[0159] 7-(Methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]-5-[[2-oxo-1-(2-pyridinyl)-3-pyridinyl]amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide

[0160]

[0161] Scheme 4 Step C: A microwave vessel was charged with 5-chloro-7-(methylamino)-N-[(3R)-1-methyl-2-oxo-pyrrolidin-3-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide (0.302 g, 0.935 mmol), 3-amino-1-(2-pyridyl)pyridin-2-one (0.21 g, 1.1 mmol), potassium acetate (281 mg, 2.7 mmol), 2-methylbutan-2-ol (7.5 mL) and 1,4-dioxane (7.5 mL). The flask was flushed with nitrogen for 5 minutes. Pd-175 [tBuBrettPhos Pd(allyl)]Otf (30 mg, 0.038 mmol) was added. The vessel was heated in a microwave at 140°C. After 40 minutes, the mixture was cooled to ambient temperature and filtered through celite. The resulting residue was purified by reverse phase chromatography to obtain the title compound (265 mg, 60%). ES / MS (m / z): 474.2 (M+H).

[0162] TYK2-JH2 tracer binding assay

[0163] The pseudokinase domain (JH2) of human JAK (Janus family of cytoplasmic tyrosine kinases) family tyrosine kinase 2 (TYK2) (Genbank NP_003322) with an N-terminal His6 tag was expressed in baculovirus and purified by HisPur Ni-NTA affinity and Superdex 200 size exclusion chromatography. The compound prepared in Preparation 17, which is a conjugate of AlexaFluor 647 dye (Thermo Fisher Scientific) with an appropriate TYK2 JH2 binder, is referred to herein as the "tracer." A 3-fold, 10-point serial dilution of the compound (Examples 1, 2, and 3) was prepared in 100% DMSO and 50 nL / well was transferred to a Proxiplate-384F white plate (PerkinElmer 6008280) using acoustic liquid handling. Control wells for determination of percent inhibition contained 100% DMSO (50 nL) and assay buffer with either tracer (2.00 nM final concentration) (minimum, low FRET) or diluted TYK2-JH2 enzyme (0.200 nM final concentration) with tracer (2.00 nM final concentration) (maximum, high FRET).

[0164] 5.0 µL of His-tagged TYK2-JH2 (0.402 nM) and LanthaScreen Eu-anti-HIS Ab (4.02 nM, LifeTech, PV5597) in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 1 mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid, 0.01% Brij-35 and Milli-Q) water were added to the Proxiplate-384 plate containing 50 nL of diluted compound and control wells. 5.0 µL of tracer (2.00 nM final concentration) in assay buffer was added to the plate and allowed to equilibrate at ambient temperature for 30 minutes. After 30 minutes, the plate was counted on a PerkinElmer Envision using the following settings: excitation (340 nm), tracer emission (665 nm), and LanthaScreen Eu-anti-His antibody emission (615 nm). The ratio of tracer emission (665 nm) to LanthaScreen Eu-anti-His antibody emission (615 nm) was determined. The percent inhibition at each inhibitor concentration was calculated using the maximum and minimum control wells and fitted to the GeneData Screener ® The four-parameter nonlinear logistic equation in the formula was used to obtain the IC of the tested compound. 50 The data described in Table 1 demonstrate that the compounds of Examples 1-3 bind to the TYK2-JH2 pseudokinase domain in vitro.

[0165] Table 1: IC provided for Examples 1-3 50 value

[0166] Compound TYK2-JH2 binding (nM) Example 1 <0.254 (n=4) Example 2 <0.254 (n=1) Example 3 <0.254 (n=3)

[0167] Inhibition of IFNα signaling through pSTAT1 in TF1 cells

[0168] TF1 cells (ATCC, CL-2003) were grown in RPMI 1640 (GIBCO) supplemented with 10% dialyzed FBS, 0.1 mg / mL ampicillin, and 2 ng / mL granulocyte macrophage colony stimulating factor. TF1 cells (100 K per well) were seeded in 96-well poly-D-lysine coated plates in serum-free DMEM and incubated overnight at 37°C under 5% CO2. Example 1 was serially diluted in DMSO, added to the cells, and incubated at 37°C for 1 hour. The cells were then stimulated with 10 ng / mL IFNα2 for 20 minutes at 37°C. After removing the culture medium, the cells were lysed in a buffer containing a Halt protease and phosphatase inhibitor cocktail (Thermo Scientific #78441) at ambient temperature for 30 minutes. The amount of p-Stat1 (Tyr701) was quantified as light emission at 615 nm using the AlphaLISA SureFire Ultra p-Stat1 (Tyr701) Assay Kit (Perkin Elmer #ALSU-PST1-A50K) according to the supplier's recommended protocol. The percent inhibition at each inhibitor concentration was calculated and analyzed using Genedata Screener ® Fit to a four-parameter nonlinear logistic equation to obtain the IC of the tested compounds expressed as geometric means with standard error of the mean (SEM) 50 The data described in Table 2 indicate that the compounds of Examples 1-3 are inhibitors of IFNα signaling through pSTAT1 in TF1 cells.

[0169] Table 2: IC provided for Examples 1-3 50 value

[0170] Compound IFNα inh (µM) Example 1 0.112 (±0.055 µM, n=4) Example 2 0.206 (±0.065 µM, n=3) Example 3 0.106 (±0.070 µM, n=3)

[0171] IL23 pSTAT3 AlphaLISA assay

[0172] IL2-dependent Kit225 cells (University of Texas MDAnderson Cancer Center) expressing the endogenous IL23 receptor were stably transduced with Lenti STAT3 Reporter (SABiosciences CLS-6028L) linked to firefly luciferase. These cells were used to monitor TYK2 activity by quantifying gene expression due to STAT3 phosphorylation after induction by IL23 in the presence of IL2 using AlphaLISA technology (TGRBiosciences ALSU-TST3-A50K). The cells were grown in RPMI 1640 (Gibco 22400) supplemented with 10% FBS (Invitrogen 10082), 1X Pen / Strep (Gibco 15140-122), 200 ng / ml Puromycin (Sigma P9620), and fresh 10 ng / ml recombinant human IL2 (R&D Systems 202-IL-50).

[0173] For assay preparation, cells were plated at 300,000 cells / well into Biocoat black poly-D-lysine coated clear bottom 384-well plates (Becton Dickinson Bio-Coat 35-4640) in DMEM (Sigma D5796) and incubated overnight at 37°C. Compounds dissolved in DMSO were serially diluted 1:3 to generate a 10-point concentration response curve (final DMSO = 0.1%). Cells were pre-incubated with Example 1 for 1 hour at 37°C and subsequently stimulated with IL23 (25 ng / mL final) for 30 minutes. After centrifugation at 2000 rpm for 10 minutes, cell pellets were lysed with a 1:1 mixture of lysis buffer (TGR Biosciences) and Halt Protease & Phosphatase Cocktail Inhibitor (Thermo Scientific 1861281) for 30 minutes. AlphaLISA reactions were performed according to the supplier's recommended protocol and luciferase levels were measured using an Envision plate reader (PerkinElmer). Relative IC was calculated using a four-parameter nonlinear logistic equation (GeneData Screener 13.0.5). 50 To obtain the IC of the tested compounds expressed as geometric mean with standard error of the mean (SEM) 50 The data described in Table 3 demonstrate that the compounds of Examples 1-3 are inhibitors of IL-23 signaling in a cell-based assay.

[0174] Table 3: IC provided for Examples 1-350 value

[0175] Compound IL-23 inh (µM) Example 1 0.065 (±0.011 µM, n=4) Example 2 0.101 (±0.0005 µM, n=2) Example 3 0.101 (±0.022 µM, n=3)

Claims

1. A compound of the following formula or a pharmaceutically acceptable salt thereof: Where R is: , or .

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the following formula: 。 3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R is: 。 4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R is: 。 5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R is: 。 6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is: 。 7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is: 。 8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is: 。 9. A compound as claimed in any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use in therapy.

10. A compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, for use in treating psoriasis.

11. A compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for use in the treatment of systemic lupus erythematosus.

12. A compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for use in the treatment of type 1 diabetes.

13. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating TYK2-mediated psoriasis.

14. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating TYK2-mediated systemic lupus erythematosus.

15. Use of the compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof for preparing a medicament for treating TYK2-mediated type 1 diabetes.

16. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents or excipients.

Citation Information

Patent Citations

  • TYK2 inhibitors and uses thereof

    US20190031664A1

  • Pyrazolo[1,5-A] pyrimidine derivatives

    US7557110B2

  • TYK2 inhibitors and uses thereof

    WO2019023468A1

  • Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus

    WO2020055636A1

  • 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives

    WO2020123225A1